Non‑small cell lung cancer therapy
The Department of Medical Oncology at General Oncological Hospital Of Kifissia Agioi Anargyroi focuses on developing innovative treatments for non‑small cell lung cancer.
- Combination of targeted agents with chemoradiation
- Integration of immunotherapy after standard treatment
- Optimizing outcomes for stage III disease
Trials aim to improve survival and quality of life by testing new drug combinations and assessing their safety in patients who cannot undergo surgery.
Radiation‑chemotherapy and immunotherapy integration
Research explores how adding immunotherapy to conventional radiation and chemotherapy regimens can enhance tumor control.
- Evaluating sequential versus concurrent treatment schedules
- Assessing response rates in unresectable stage III lung cancer
- Monitoring long‑term tolerability of combined modalities
The goal is to determine whether the addition of agents like Durvalumab after chemoradiation provides a measurable benefit for patients with advanced disease.
